Director, Communications

Jennifer Freiling

Freiling joined atai Life Sciences as Director of Communications in August of 2022. Previously Freiling was VP, Marketing and Commercial Operations at Quantgene a liquid-biopsy-based early-stage biotech company where she served on the leadership team. Freiling was responsible for the planning and execution of all commercial and marketing activity for the company’s personalized precision medicine service, Serenity, and its COVID-19 business unit. Through Freiling’s leadership, the company was able to grow over 2 years from pre-revenue to over $40MM in revenue through its enterprise COVID testing services.

Prior to that, Freiling served as Group Account Director at Wunderman Health overseeing multiple pieces of business with a focus on data-driven marketing including the launch of Janssen’s esketamine, Jennifer brings with her 16 years of healthcare marketing and communications experience. She has deep expertise in strategic patient-centric marketing having worked with world-leading companies including Gilead, J&J, Merck, Sanofi and Lilly. She has also led the launch of several pharmaceutical brands including Cialis for BPH, Sanofi’s insulin Toujeo and the omni-channel support platform for Gilead’s Hepatitis C portfolio.

Freiling has a B.A. in Psychology from Columbia University’s Barnard College. She also spent 9 years growing up in Tokyo Japan; an experience that has deepened her appreciation and skills for effective target-centric communication.

<<  Back to our team